Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BCYC
BCYC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BCYC News
Bicycle Therapeutics Presents Five Abstracts at AACR Annual Meeting 2026
Mar 18 2026
Newsfilter
Bicycle Therapeutics Restructures and Lays Off 30% of Workforce
Mar 17 2026
seekingalpha
Bicycle Therapeutics Q4 Earnings Exceed Expectations
Mar 17 2026
seekingalpha
Bicycle Therapeutics Appoints New CFO
Feb 03 2026
seekingalpha
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
Dec 16 2025
Businesswire
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
Dec 16 2025
Newsfilter
Bicycle Therapeutics Under Investigation, ADR Price Drops 7.88%
Dec 11 2025
PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
Nov 20 2025
PRnewswire
Citizens Upholds Outperform Rating for Bicycle Therapeutics plc - Depositary Receipt (BCYC) Market
Nov 01 2025
NASDAQ.COM
Citizens Upgrades Bicycle Therapeutics to Market Outperform and Increases Price Target to $12
Oct 31 2025
Benzinga
Itron Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday
Oct 31 2025
Benzinga
4 Analysts Assess Bicycle Therapeutics: What You Need To Know
Aug 12 2025
Benzinga
JMP Securities Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $10
Aug 12 2025
Benzinga
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Jul 31 2025
Newsfilter
Demystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews
Jul 17 2025
Benzinga
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 02 2025
Newsfilter
Show More News
